VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | COVID-19 and MPN

VJHemOnc is committed to improving our service to you

John Mascarenhas

John Mascarenhas, MD, of the Icahn School of Medicine at Mount Sinai, New York, NY, outlines the the impact of COVID-19 on the treatment and management of patients with myeloproliferative neoplasms (MPNs), including reducing nosocomial infection risk in myelofibrosis patients, changes in clincial trial enrollment, as well as highlighting a role of ruxolitinib in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter